The Multidisciplinary Association for Psychedelic Studies has achieved yet another landmark milestone in the modern psychedelic renaissance: raising $30 million in non-profit donations in less than six months to make MDMA a medicine. The funding is specifically meant to propel MDMA through phase 3 clinical trials, a remarkable feat in the movement to medicalize psychedelic compounds. The organization worked in collaboration with the popular entrepreneur, author and biohacker, Tim Ferris and many other notable leaders in the space, who collectively helped match the $10 million-dollar raise with an equal contribution of their own. MAPS’ momentous 2019 publication examining six phase-two randomized controlled trials helped establish sound rationale for progressing to phase 3.1 In completing this capstone challenge, the organization has just made a dramatic leap towards making their dream of seeing MDMA become a medicine into a reality. Once successful, this will mark the first-ever psychedelic assisted psychotherapy to win approval from the FDA.

 

American Entrepreneur, Podcaster, & Author Tim Ferris & Notable Others Match $10M In Donations

 

Acclaimed American entrepreneur, podcaster and author, Tim Ferriss, committed the first $1 million for the Capstone Challenge matching grant, and was soon joined by the Steven & Alexandra Cohen Foundation ($5 million), James Bailey ($1 million), Blake Mycoskie ($1 million), Peter Rahal ($1 million), and John A. Griffin ($1 million). Other notable donors include:

 

  • The Bob & Renee Parsons Foundation – $1,929,000
  • The Fournier Family Foundation, Inc. – $1,000,000
  • Valor Equity Partners – $1,000,000
  • Anonymous – $1,000,000
  • Anonymous – $750,000
  • Ryan and Maggie McKillen – $500,000
  • Peter Attia – $300,000
  • Justin Rosenstein – $300,000
  • George Goldsmith and Katya Malievskaia – $300,000
  • Anonymous – $300,000

 

The revival of the modern psychedelic renaissance is fueled by research and innovation pioneered by these individuals and organizations. Individuals can directly donate to MAPS to help further the novel field of psychedelic science and establish radically effective new treatments for mental health and psychospiritual development. The team at Microdose Psychedelic Insights will certainly follow the latest developments in research and policy breakthroughs in the psychedelic revolution.

 

Works Cited

 

  1. Mithoefer, M. C. et al. MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology (Berl.) 236, 2735–2745 (2019).